BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Spinraza (Nusinersen) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Spinraza (Nusinersen)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05067790-10799@assetmemo.bio
DTSTAMP:20261121T004511Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Spinraza (Nusinersen): Phase 3 readout est. (NCT05067790)
DESCRIPTION:Spinraza (Nusinersen)\, phase 3\, Spinal Muscular Atrophy.\nStu
 dy: A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB0
 58) Given as Injections to Participants With Spinal Muscular Atrophy (SMA)
  Who Were Previously Treated With Risdiplam (ASCEND)\nEstimated primary co
 mpletion: 24 September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nusinersen#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05067790
URL:https://assetmemo.bio/drug/nusinersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06555419-10799@assetmemo.bio
DTSTAMP:20261121T004511Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Spinraza (Nusinersen): Phase 1 readout est. (NCT06555419)
DESCRIPTION:Spinraza (Nusinersen)\, phase 1\, Spinal Muscular Atrophy.\nStu
 dy: A Study to Find Out How Nusinersen is Processed in the Body When Given
  Through the ThecaFlex DRx™ System in Adult and Pediatric Participants W
 ith Spinal Muscular Atrophy (PIERRE-PK)\nEstimated primary completion: 30 
 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nusin
 ersen#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06555419
URL:https://assetmemo.bio/drug/nusinersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047144-10799@assetmemo.bio
DTSTAMP:20261121T004511Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Spinraza (Nusinersen): Phase 2 readout est. (NCT07047144)
DESCRIPTION:Spinraza (Nusinersen)\, phase 2\, Spinal Muscular Atrophy.\nStu
 dy: A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Tha
 n 2 Years Old and Have Spinal Muscular Atrophy\nEstimated primary completi
 on: November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nu
 sinersen#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07047144
URL:https://assetmemo.bio/drug/nusinersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07846696-10799@assetmemo.bio
DTSTAMP:20261121T004511Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Spinraza (Nusinersen): Phase 3 readout est. (NCT07846696)
DESCRIPTION:Spinraza (Nusinersen)\, phase 3\, Spinal Muscular Atrophy.\nStu
 dy: An Open Label Individual Patient (OLIP)-02 Study of Nusinersen (BIIB05
 8)\nEstimated primary completion: 31 December 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/nusinersen#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07846696
URL:https://assetmemo.bio/drug/nusinersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07838779-10799@assetmemo.bio
DTSTAMP:20261121T004511Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Spinraza (Nusinersen): Phase na readout est. (NCT07838779)
DESCRIPTION:Spinraza (Nusinersen)\, phase na\, Spinal Muscular Atrophy.\nSt
 udy: An OLIP Study (Open Label Individual Patient) of Nusinersen in a Part
 icipant With Spinal Muscular Atrophy Who Previously Participated in an Inv
 estigational Study With Nusinersen\nEstimated primary completion: 31 Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nusinersen#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0783
 8779
URL:https://assetmemo.bio/drug/nusinersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
